Good
Mostly Aligned
Patient Risk:
Info
Summary
Most safety/risk and general dosing principles align with provided label excerpts (Warnings and Precautions 5.1–5.4, Dosage Modifications 2.2, and Medication Guide counseling 17). Several specific/operational claims (indication wording and tablet strength availability) are not verifiable from the excerpts provided, and multiple 'typically advised/monitored' statements are broader than the provided monitoring text.
Category Scores
Accurate Statements
Iclusig can cause serious vascular and clotting risks, including arterial and venous events.
Supported by Warnings and Precautions: 5.1 Arterial Occlusive Events and 5.2 Venous Thromboembolic Events; Medication Guide reiteration includes blood clots/blockage in arteries and veins (17).
The dose and schedule of Iclusig depend on the patient’s diagnosis and how the disease responds.
Supported generally by label structure indicating dosage modifications based on adverse reactions with management (2.2) and by Warnings guidance to interrupt/resume/discontinue based on recurrence/severity (5.1–5.4). (Direct dosing-by-diagnosis wording not provided in excerpts.)
Clinicians may adjust dosing over time based on disease response.
Supported generally by dosage modification approach tied to clinical status and recurrence/severity (2.2; 5.1–5.4). (Explicit 'disease response' phrasing not provided in excerpts.)
Clinicians typically monitor liver tests.
Supported by 5.4 Hepatotoxicity: 'Monitor liver function tests at baseline, then at least monthly or as clinically indicated.'
Clinicians typically monitor blood chemistry.
Partially supported via 5.4 hepatotoxicity monitoring of liver function tests; 'blood chemistry' is broader than excerpt.
Clinicians typically monitor blood counts.
No direct excerpt provided for blood count monitoring; not verifiable from supplied text.
Clinicians typically monitor signs of vascular or thrombotic complications.
Supported generally by 5.1 'Monitor for evidence of AOEs' and 5.2 'Monitor for evidence of VTEs.'
Clinicians typically monitor ongoing response to therapy.
No direct excerpt provided for response monitoring; not verifiable from supplied text.
Unsupported Statements
Iclusig (ponatinib) is an oral cancer medicine.
No excerpt provided stating oral route; only dosage form strengths (oral film-coated tablets) were provided, but not an FDA label excerpt text for this claim.
Iclusig (ponatinib) is used to treat certain types of chronic myeloid leukemia (CML).
Indication language and approval criteria are not provided in the excerpts supplied.
Iclusig (ponatinib) is used to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Indication language is not provided in the excerpts supplied (no section showing approved indications/criteria).
The 30 mg tablet strength is one of the available tablet doses of ponatinib.
Strengths were listed in the prompt as '10 mg, 15 mg, 30 mg, 45 mg', but no direct FDA label excerpt confirming the 30 mg availability was provided.
Iclusig is prescribed for patients with CML or Ph+ ALL who have specific prior treatment history and disease characteristics.
No approved indication criteria or prior-treatment/disease characteristic requirements were included in the supplied label excerpts.
Iclusig may be prescribed for patients after other tyrosine kinase inhibitors were used.
No indication/eligibility criteria excerpt provided to verify prior TKI treatment language.
Iclusig may be prescribed when the cancer has particular resistant or intolerant behavior.
No indication eligibility excerpt provided to verify 'resistant'/'intolerant' criteria.
Iclusig can cause other drug-related effects that require monitoring.
General monitoring statements are not tied to specific label wording; only specific monitoring items (AOE/VTE/HF/hepatotoxicity) are in excerpts.
Patients are typically advised to report symptoms that could suggest blood flow problems, such as chest pain.
Medication Guide excerpt provided only broad statements (blood clots/blockage in arteries and veins, heart problems, liver problems); no specific symptom examples like chest pain are provided.
Patients are typically advised to report symptoms that could suggest blood flow problems, such as shortness of breath.
No specific symptom examples are provided in the supplied Medication Guide excerpt.
Patients are typically advised to report symptoms that could suggest blood flow problems, such as severe headache.
No specific symptom examples are provided in the supplied Medication Guide excerpt.
Patients are typically advised to report symptoms that could suggest blood flow problems, such as weakness on one side.
No specific symptom examples are provided in the supplied Medication Guide excerpt.
Clinicians typically monitor blood counts.
No blood count monitoring statement is present in provided excerpts.
Clinicians typically monitor ongoing response to therapy.
No excerpt provided for response-to-therapy monitoring.
Contradictions
Important Omissions
Boxed warning status (presence/wording) was not evaluated because no boxed-warning excerpt text was provided in the prompt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Safety-related claims about arterial/venous clotting risks and need for monitoring are broadly consistent with provided Warnings and Precautions and Medication Guide. However, several 'typically advised/monitored' statements include specific symptoms or monitoring items not supported by the provided excerpts, which could overstate label specificity.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some indication eligibility details and specific patient symptom examples/monitoring items are not supported by the provided label excerpts.
Suggested Improvement
Limit counseling and monitoring statements to the specific label monitoring guidance provided (e.g., AOE/VTE monitoring, liver function tests) and avoid listing specific symptom examples unless the Medication Guide excerpt text containing those examples is provided.